spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Adaptive Designs in Clinical Trials

SMI - Adaptive Designs in Clinical Trials

9-10 April 2018
Copthorne Tara Hotel, Scarsdale Place, Kensington, London, UK

Now running for 10 years, SMiís annual conference on  Adaptive Designs in Clinical Trials will return to London on 9thand 10th April 2018.

This yearís agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug, medical device and therapy development.

Giving you a fresh take on this vital area of biopharma, the event will ride the wave of technology within the pharmaceutical industry, as we consider how the increasing use of smartphone apps and digital devices is changing the way trials run. Simultaneously, the event will also explore how adaptive designs are being used for the production of personalised medicines and personalised therapies.

Featured Speakers include:

  • James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
  • Alex Sverdlov, Director, Statistical Scientist, Novartis
  • Frank Fleisher, Principal Methodology Statistician, Boehringer-Ingelheim
  • Christine Fletcher, Executive Director Biostatistics, Amgen
  • Chris Harbron, Principal Statistical Scientist, Roche
  • Olivier Collignon, Biostatistician, European Medicines Agency
  • Beatrice Panico, Medical Advisor, MHRA
  • Corine Baayen, Senior Biostatistician, H.Lundbeck

Key Highlights

  • Explore the current industry outlook and evaluate the promises and challenges of digital technology use
  • Hear exciting case studies on enrichment designs and group sequential trials
  • Discover how big pharma companies are using Platform Trials and self-adapting priors to advance their adaptive clinical trials
  • Examine the use of adaptive clinical trials are used to produce targeted therapies
  • Learn from the latest regulatory perspectives from MHRA and EMA, including planning and assessing umbrella and basket trials

Early Bird: Book by Dec 15 to save £400. Book by Jan 31 to save £200. Book by 28 Feb to save £100.

Contact details of organiser

Alan Caddick | Senior Marketing Executive | SMi Group Ltd 
T: +44 (0) 207 827 6038 | acaddick@smi-online.co.uk

phone +44 207 827 6000
email events@smi-online.co.uk
web bit.ly/2mTgPPv
email Copthorne Tara Hotel, Scarsdale Place, Kensington, London
 
Print this page
Send to a friend
   
spacer
Industry Events

14th Annual Biomarkers & Immuno-Oncology World Congress

11-13 June 2018, Westin Boston Waterfront, Boston, Massachusetts

The Biomarkers and Immuno-Oncology World Congress brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providersómaking the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

Banner of ChinaBio_Events_102 on Samedan
White Papers

Driving ROI: The Case for Investing in Contract & Site Regulatory Document Management Services

DrugDev

With tight timelines and complicated regulatory documentation requirements, getting a clinical trial up and running quickly is easier said than done. Key milestones can be achieved only after the successful negotiation of clinical trial agreements and completion of essential regulatory documents. Many clinical trials are hindered by inefficient, labor-intensive processes. Prolonged, inefficient activation can hamper investigator satisfaction and, ultimately, have a negative bottom-line impact for sponsors and CROs. In addition, the Sunshine Act is heightening the importance of financial disclosure in clinical trials. Without a robust financial disclosure strategy, sponsors cannot ensure that physician self-reported financial disclosure data are aligned with the payment data being reported through the Sunshine Act, increasing financial and regulatory risk.
More info >>


News and Press Releases

Source BioScience invest in digital pathology platform to enhance the outsourced histopathology service solution provided to the NHS and private healthcare

As a leading provider of outsourced histopathology services to the NHS and private healthcare centres in the UK Source BioScience has, after a detailed review of all other available alternatives in the digital marketplace, unveiled investment in a digital pathology platform from their preferred partner, Philips.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement